Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease — Massimo Filippi (2023) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease
Shared by
Massimo Filippi
MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease
Article
2023
en
Authors
Massimo Filippi
GC
Giordano Cecchetti
FA
Federica Agosta
Abstract
1 min read
Structural MRI will play a crucial role in the upcoming era of amyloid-lowering mAbs against Alzheimer's disease, from the correct patient selection to the monitoring of adverse events and of disease progression.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2018
MRI of non-Alzheimer's dementia: current and emerging knowledge
Massimo Filippi
,
Federica Agosta
Article
2023
Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer’s disease: an expert opinion and practical guideline
Massimo Filippi
,
Giordano Cecchetti
,
Annachiara Cagnin
,
Camillo Marra
,
Flavio Nobili
,
Lucilla Parnetti
,
Federica Agosta
Article
2007
Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Kate M. Webber
,
Gemma Casadesús
,
Richard L. Bowen
,
George Perry
,
Mark A. Smith
Article
2007
The Pathology of Alzheimer Disease Elicits an In Vivo Immunological Response
David Bonda
,
Kate M. Webber
,
Sandra L. Siedlak
,
George Perry
,
Robert P. Friedland
,
Mark A. Smith
Article
2011
Neurodegenerative Processes In Alzheimer‘s Disease: An Overview of Pathogenesis With Strategic Biomarker Potential
Kasia Gustaw Rothenberg
,
Sandra L. Siedlak
,
Hyoung‐gon Lee
,
Xiongwei Zhu
,
George Perry
,
Mark A. Smith
Discussion(0)
No comments yet. Be the first to comment.